Home
News
Create
Screeners
Insights
Venmax Drugs & Pharmaceuticals
24.
65
-0.74
(-2.91%)
Market Cap
₹21.65 Cr
PE Ratio
25.65
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-2.91%
1M
+3.14%
6M
-30.15%
1Y
+20.71%
5Y
+274.62%
View Company Insights
Latest news about Venmax Drugs & Pharmaceuticals
Venmax Drugs Reports Q3FY26 Results with ₹162.06 Lakhs Revenue & Fund Compliance
Feb 07, 2026
Venmax Drugs & Pharmaceuticals achieved significant financial recovery in Q3FY26 with revenue of ₹162.06 lakhs and net profit of ₹3.21 lakhs, compared to a loss of ₹49.52 lakhs in the previous year. The company also maintained compliance with fund utilization requirements for its ₹20.05 crores preferential issue, with ₹3.98 crores utilized without any deviation from stated objectives.
Venmax Drugs Allots 7.75 Lakh Equity Shares Through Warrant Conversion Worth ₹1.16 Crores
Jan 21, 2026
Venmax Drugs & Pharmaceuticals: Independent Director Dakshita Jain Steps Down
Nov 24, 2025
Venmax Drugs Reports Strong Revenue Growth and Advances Amalgamation with Hatri Pharma
Nov 12, 2025
Venmax Drugs & Pharmaceuticals Reports Rs 3.74 Lakh Profit in Q1 Results
Jul 23, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO